Atommap's physics-based and ML-augmented computational drug discovery platform has powered Silicon Therapeutics and Roivant Discovery to deliver a clinical stage STING agonist, potent inhibitors against a high-valued but challenging oncology target, and active molecules for therapeutic degradation of target proteins.